FDA Clears Corbus to Start Registrational Study for CRB-701 in Throat Cancer
CRBP sits 29% above its 52-week low of $7.12.
Summary
The FDA has cleared Corbus to begin the TEMPO-1 registrational study of CRB-701 in second-line oropharyngeal cancer, with enrollment starting in September 2026. This is a major de-risking event for the lead asset, moving it into a pivotal trial that could support approval. It follows positive Phase 1/2 data in May 2026 that showed strong efficacy but also triggered a 31% stock drop on safety concerns. The clearance signals the FDA is comfortable with the risk-benefit profile enough to allow a registration path. With a $168M market cap and a $300M shelf already registered, successful execution here is critical for the company's future.
At the time of this announcement, CRBP was trading at $9.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.2M. The 52-week trading range was $7.12 to $20.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.